Scalable Production of a De Novo SARS-CoV-2 Antiviral Miniprotein in Escherichia coli
Authors:
- Jinhwan ShinJSJinhwan Shin
- Eu-Min KimEKEu-Min Kim
- Jun-Hong JangJJJun-Hong Jang
- Seok-Won JeeSJSeok-Won Jee
- Sang-Hoon KimSKSang-Hoon Kim
- Seonggwan YuSYSeonggwan Yu
- Minguen YoonMYMinguen Yoon
- Daniel CraigDCDaniel Craig
- Ryan SwoyerRSRyan Swoyer
- Sandip PatelSPSandip Patel
- Praveen AlamuriPAPraveen Alamuri
- Albert PriceAPAlbert Price
Open Access
- 3 September 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (9) , 1110
Abstract
Background/Objectives: The rapid emergence of SARS-CoV-2 variants that evade neutralizing antibodies underscores the need for new antiviral biologics that integrate precise molecular design with scalable, cost-effective manufacturing. Computationally designed miniproteins targeting the spike protein’s receptor-binding domain (RBD) offer a promising alternative to monoclonal antibodies because of their small size, high thermal stability, and compatibility with microbial expression systems. Here, we detail the full development and cGMP manufacturing of IPD-52520, a novel antiviral miniprotein produced using an optimized E. coli platform. Methods: Two candidate miniproteins, a homotrimeric construct (Trimer, IPD-52520, 17 kDa) and a tandem fusion construct (Daisy, IPD-52521, 25 kDa), were evaluated in parallel through systematic optimization of strain selection, media formulation, fed-batch fermentation, inclusion-body solubilization, refolding, and chromatographic purification. The leading candidate was scaled from 5 L to 50 L under cGMP conditions, and biophysical and stability analyses were conducted to support nonclinical and Phase 1 clinical development. Results: The Trimer was selected as the lead molecule based on superior preclinical efficacy, favorable pharmacokinetics, and higher volumetric yields. The optimized process yields about 2 g/L of purified protein at over 90% purity. Scale-up from 5 L to 50 L demonstrated excellent batch consistency across six independent runs. Biophysical studies confirmed a well-folded, predominantly alpha-helical trimer (Tm = 73.4 °C; polydispersity = 1.005) with an intact primary structure and strong target binding (KD < 1 pM). Stability studies show the drug remains stable at 2–8 °C for at least 12 months, with ongoing long-term studies. Conclusions: These findings demonstrate that computationally designed antiviral miniproteins can be translated into scalable biologics and establish a platform for rapid therapeutic development against current and future pandemics.Keywords
Funding Information
- Bill and Melinda Gates Foundation (INV-035430)
This publication has 26 references indexed in Scilit:
- Designed miniproteins potently inhibit and protect against MERS-CoVCell Reports, 2025
- Preclinical proof of principle for orally delivered Th17 antagonist miniproteinsCell, 2024
- Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and diseaseCell Host & Microbe, 2021
- Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2Cell, 2020
- Miniproteins as a Powerful Modality in Drug DevelopmentTrends in Biochemical Sciences, 2020
- What has de novo protein design taught us about protein folding and biophysics?Protein Science, 2019
- De novo design of potent and selective mimics of IL-2 and IL-15Nature, 2019
- Massively parallel de novo protein design for targeted therapeuticsNature, 2017
- The coming of age of de novo protein designNature, 2016
- Challenges and opportunities for non-antibody scaffold drugsDrug Discovery Today, 2015